By Howard Lovy Gene-silencing siRNA technology has failed to live up to its original hype largely because of problems delivering short interfering RNA to the precise spot where it’s needed. Alnylam Pharmaceuticals ($ALNY), a Cambridge, MA company focused on RNAi-based therapeutics, together with partners at MIT, think they’ve found a solution. A release says they …
By Ryan McBride Big Blue’s cloud has helped Swiss scientists in their hunt for clues about how certain bacteria form resistance against antibiotics and cause disease. It’s perhaps the latest case where the tech giant ($IBM) has been aiding life sciences concerns in managing and analyzing biological or clinical data in the cloud. For this …
By John Carroll Third Rock Ventures is taking $26 million out of its latest fund to bankroll another upstart biotech. In joint announcements rolled out bright and early today the venture group took the wraps off of Lotus Tissue Repair and announced an in-licensing deal for protein replacement technology that will initially target an ultra-rare …
By John Carroll Anyone looking for an example of how drug development partnerships work now at Sanofi should check out the new development pact it inked with Audion Therapeutics. Its unit charged with finding new drugs to combat the effects of aging will collaborate with Audion on discovering small molecules to treat hearing loss through …
By John Carroll NIH chief Francis Collins made waves in the research community with his ambitious plans to build a new center designed to speed up the high-risk business of chaperoning new drugs out of the lab and toward advanced clinical trials. By NIH standards, Collins was moving at light-speed by projecting a launch date …
BOSTON – May 10, 2011 – U.S. regulatory approvals for new biopharmaceuticals nearly doubled in the last decade, compared to the 1990s, according to the Tufts Center for the Study of Drug Development, but drug developers “face substantial challenges” if they are to maintain that pace, the study’s author says. During the 2000-09 period, 65 …
By John Carroll Pfizer’s quest to find a more productive way to discover and advance important new treatments is taking the pharma giant on a journey back to college in Boston. With some of Pfizer’s R&D luminaries joining hands with top politicians, the company announced a $100 million, five-year plan to establish a new Center …
By John Carroll Just after Pfizer wowed Wall Street with its promise to slash billions in R&D costs–while hinting at plans to spin off its non-pharma businesses–Merck CEO Kenneth Frazier (photo) caused something of a letdown as he promised to keep the pedal to the metal on its $8 billion-plus R&D budget for the year. And …
The Relay Innovation Engine aggregates scientific and market data in real-time and provides competitive business intelligence to life sciences professionals. The Relay Innovation Engine powers Business Development Live! (BD Live!) for Biotechnology & Pharmaceutical companies, and Technology Transfer Live! (TT Live!) for University Technology Transfer Offices......Read More